FDA gives tentative nod to Zydus Cadila for generic Rytary

Press enter to search
Close search
Open Menu

FDA gives tentative nod to Zydus Cadila for generic Rytary

By Sandra Levy - 08/03/2020

Patients with Parkinson’s disease will soon have a new generic to treat their condition.

The Food and Drug Administration has given a tentative nod to Zydus Cadila for carbidopa and levodopa extended-release capsules in dosage strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

The product is the generic of Impax Labs’ Rytary.

The medication is used to treat the symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Related Topics